BRCA1 and ovarian cancer: A synergistic enhancement in pRPA32 phosphorylation in replicating cells (EdU+ cells) upon treatment with DHS and talazoparib was even observed in lower concentration of DHS in SK‐OV‐3 cells (Figure S36A,B, Supporting Information) and other BRCA1/2 wild‐type ovarian cancer cell lines PA‐1 (Figure S37A–C, Supporting Information), OAW42(Figure S38A–C, Supporting Information) and A2780 (Figure S39A–C, Supporting Information).